A drug is not a drug is not a drug: A commentary

Pharmacoepidemiology and Drug Safety

Volumn 11, Issue 6, 2002, Pages 437-438

  Struijker Boudier, H A J ^a  

^a MAASTRICHT UNIVERSITY   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DRUG; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PROPRANOLOL;

ANALYTIC METHOD; ANIMAL MODEL; CLINICAL PRACTICE; DRUG APPROVAL; DRUG CHOICE; DRUG DEVELOPMENT; DRUG INTERACTION; DRUG LABELING; DRUG MARKETING; DRUG SAFETY; DRUG THERAPY; DRUG UTILIZATION; DRUG WITHDRAWAL; ECONOMIC ASPECT; EDITORIAL; EUROPE; FOLLOW UP; FOOD AND DRUG ADMINISTRATION; LONG TERM CARE; METHODOLOGY; NETHERLANDS; NONHUMAN; PHARMACODYNAMICS; POSTMARKETING SURVEILLANCE; PRIORITY JOURNAL; RAT; REGISTRATION; REIMBURSEMENT; TIME; UNITED STATES;

ANTI-BACTERIAL AGENTS; CYTOCHROME P-450 ENZYME SYSTEM; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG APPROVAL; DRUG LABELING; DRUG THERAPY; DRUG UTILIZATION REVIEW; HUMANS; PRODUCT SURVEILLANCE, POSTMARKETING; RISK ASSESSMENT; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 0036750089     PISSN: 10538569     EISSN: None     Source Type: Journal    
DOI: 10.1002/pds.767     Document Type: Editorial

References (5)

1. Cross J, Lee H, Westelinck A, Nelson J, Grudzinskas C, Peck C. Post-marketing drug dosage changes of 499 FDA-approved new molecular entities, 1980-1999. Pharmacoepidemiol Drug Safe 2002; 11: 439-446.
2. Heerdink ER, Urquhart J, Leufkens HG. Changes in prescribed drug doses after market introduction. Pharmacoepidemiol Drug Safe 2002; 11: 447-453.
3. US Food and Drug Administration. Guidance for industry: population pharmacokinetics. Available at: http://www.fda.gov/cder/guidance/index.htm. [4 September 2002]
4. Cars O, Molstad S, Melander A. Variation in antibiotic use in the European Union. The Lancet 2001; 357: 1851-1853.
5. Smits JFM, Coleman TG, Smith TL, Kasbergen CM, Van Essen H, Struijker Boudier HAJ. Antihypertensive effect of propranolol in conscious SHR: central hemodynamics, plasma volume and renal function during beta-blockade with propranolol. J Cardiovasc Pharmacol 1982; 4: 903-914.